Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
Frontiers in PharmacologyBackgroundTeriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use.ObjectiveTo investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for ...
Ming-Tao Wen +11 more
doaj +3 more sources
Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. [PDF]
PLoS ONE, 2017 Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of
Akiho Fukuda +12 more
doaj +3 more sources
Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database [PDF]
Journal of Managed Care & Specialty Pharmacy, 2018 Data on adverse drug events (ADEs) observed at the population level provide important evidence regarding the safety of a pharmaceutical product in real-world settings. Recent patterns in serious and fatal ADE reporting have not been documented.To assess recent patterns in serious and fatal ADE reports in the United States.We conducted a retrospective ...
Kalyani Sonawane +2 more
openalex +4 more sources
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system [PDF]
BMC Pharmacology and Toxicology, 2020 Background To describe and analyze the patterns of adverse events associated with dipeptidyl peptidase-4 inhibitors (DPP-4is) (sitagliptin, saxagliptin, linagliptin, vildagliptin, and alogliptin) from the FDA Adverse Event Reporting System (FAERS) and to
Jing Huang +3 more
doaj +2 more sources
Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system. [PDF]
PLoS ONEAssessing the potential for oseltamivir-induced liver damage is essential to ensure its safe administration. The aim of this study was to examine the association between hepatotoxicity and oseltamivir use and to describe the features of oseltamivir ...
Lurong Yu, Qiumeng Xiang, Limei Liu
doaj +2 more sources
Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database [PDF]
Scientific ReportsRhabdomyolysis is a potentially fatal adverse reaction mainly caused by certain medications. Few real-world studies have shown a clear association between atypical antipsychotics and rhabdomyolysis.
Yi Yin, Jie Jiang, Youpeng Jin
doaj +2 more sources
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Scientific ReportsTafamidis is the world's first and only oral drug approved to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM). Medicines are known to have different adverse reactions during the course of treatment.
Fan Wu, He Zhu, Yue Zhang
doaj +3 more sources
A Standardized Dataset of a Spontaneous Adverse Event Reporting System [PDF]
Healthcare, 2022 One of the largest spontaneous adverse events reporting databases in the world is the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Unfortunately, researchers face many obstacles in analyzing data from the FAERS database. One of the major obstacles is the unstructured entry of drug names into the FAERS, as reporters might ...
Mohammad Ali Khaleel +4 more
openaire +2 more sources
Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
Vaccines, 2022 In December 2020, the U.S. Food and Drug Administration licensed COVID-19 vaccines for emergency use authorization. We investigated the ocular adverse event reports in patients reported to the Vaccine Adverse Event Reporting System (VAERS) following ...
Cyril N. A. Nyankerh +2 more
doaj +1 more source
Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
Expert Opinion on Drug Safety, 2023 Migraine has a high prevalence in the population and accounts for 12% of primary headaches. Ubrogepant is used for the treatment of acute migraine, and although some clinical trials have demonstrated the safety of Ubrogepant, its long-term safety in a large sample of the population remains to be investigated. We collected data from the US Food and Drug
Bing, Cao +5 more
openaire +2 more sources